Abstract:Background: Given the high incidence and high mortality of cervical cancer (CC) among women in developing countries, identifying reliable biomarkers for the prediction of prognosis and therapeutic response is crucial. We constructed a prognostic signature of cuproptosis-related long non-coding RNAs (lncRNAs) as a reference for individualized clinical treatment. Methods: A total of seven cuproptosis-related lncRNAs closely related to the prognosis of patients with CC were identified and used to construct a prognostic signature via least absolute shrinkage and selection operator regression analysis in the training set. The predictive performance of the signature was evaluated by Kaplan–Meier (K-M) analysis, receiver operating characteristic (ROC) analysis, and univariate and multivariate Cox analyses. Functional enrichment analysis and single-sample gene set enrichment analysis were conducted to explore the potential mechanisms of the prognostic signature, and a lncRNA–microRNA–mRNA network was created to investigate the underlying regulatory relationships between lncRNAs and cuproptosis in CC. The associations between the prognostic signature and response to immunotherapy and targeted therapy were also assessed. Finally, the prognostic value of the signature was validated using the CC tissues with clinical information in my own center. Results: A prognostic signature was developed based on seven cuproptosis-related lncRNAs, including five protective factors (AL441992.1, LINC01305, AL354833.2, CNNM3-DT, and SCAT2) and two risk factors (AL354733.3 and AC009902.2). The ROC curves confirmed the superior predictive performance of the signature compared with conventional clinicopathological characteristics in CC. The ion transport-related molecular function and various immune-related biological processes differed significantly between the two risk groups according to functional enrichment analysis. Furthermore, we discovered that individuals in the high-risk group were more likely to respond to immunotherapy and targeted therapies including trametinib and cetuximab than those in the low-risk group. Finally, CC tissues with clinical data from my own center further verify the robustness of the seven-lncRNA risk signature. Conclusion: We generated a cuproptosis-related lncRNA risk signature that could be used to predict prognosis of CC patients. Moreover, the signature could be used to predict response to immunotherapy and chemotherapy and thus could assist clinicians in making personalized treatment plans for CC patients.

Panel of Seven Long Noncoding RNA As a Candidate Prognostic Biomarker for Ovarian Cancer.

Identification and Validation of a Seven Cuproptosis-Associated Lncrna Signature to Predict the Prognosis of Endometrial Cancer

Identification and validation of an m7G-related lncRNAs signature for predicting prognosis, immune response and therapy landscapes in ovarian cancer

A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancer.

Identification of a seven-lncRNAs panel that serves as a prognosis predictor and contributes to the malignant progression of laryngeal squamous cell carcinoma

A Seven Long-Noncoding RNA Signature Predicts Prognosis of Lung Squamous Cell Carcinoma.

A Combined Long Noncoding RNA Signature as a Candidate Prognostic Biomarker for Ovarian Cancer

LncRNA Profile Study Reveals a Seven-Lncrna Signature Predicts the Prognosis of Patients with Colorectal Cancer

A Novel Seven-Long Non-Coding RNA Signature Predicts Survival in Early Stage Lung Adenocarcinoma

An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients

A 7-Lncrna Signature Associated with the Prognosis of Colon Adenocarcinoma

Long Non-Coding RNA LINC01627 is a Prognostic Risk Factor for Epithelial Ovarian Cancer.

Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer

Identification and Validation of Seven Prognostic Long Non-Coding RNAs in Oral Squamous Cell Carcinoma.

Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients

A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy

Senescence-Related LncRNAs: Pioneering Indicators for Ovarian Cancer Outcomes

Identification of pathological grade and prognosis‐associated lncRNA for ovarian cancer

The Prognostic Value of a Seven-Lncrna Signature in Patients with Esophageal Squamous Cell Carcinoma: a Lncrna Expression Analysis

Identification of the 11-Lncrna Signatures Associated with the Prognosis of Endometrial Carcinoma.

Identification of a novel nine-SnoRNA signature with potential prognostic and therapeutic value in ovarian cancer